U.S. Markets closed

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6400+0.1900 (+5.51%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.6500
Open3.5700
Bid3.4600 x 1100
Ask3.4700 x 900
Day's Range3.4200 - 3.6400
52 Week Range2.0100 - 12.0300
Volume335,860
Avg. Volume1,456,331
Market Cap285.625M
Beta (5Y Monthly)-0.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bellus Health, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit
    GlobeNewswire

    Bellus Health, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit

    Investors with losses are encouraged to contact the firm before May 17, 2021; click here to submit trade information LOS ANGELES, May 16, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Bellus Health, Inc. (NASDAQ: BLU) investors that acquired shares between September 5, 2019 and July 5, 2020. Investors have until May 17, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. Before the market opened on July 6, 2020, BELLUS announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough. According to Bellus, the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.” Bellus’ stock price fell $9.05, or 75%, on this news, over two consecutive trading sessions to close at $2.97 on July 8, 2020, thereby injuring investors. It is alleged in this complaint that Bellus made materially misleading and/or false statements, as well as failed to disclose material adverse facts about Bellus’ business, operations, and prospects. Specifically, the complaint alleges that Bellus knew, and failed to disclose, that while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

  • Business Wire

    BLU FINAL DEADLINE ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action – BLU

    WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the "Class Period"), of the important May 17, 2021 lead plaintiff deadline.

  • Business Wire

    Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.

    Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the "Class Period").